<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cholinergic Neurons in Adult Polyglucosan Body Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Glycogen Storage Disorders / Cholinergic System</td>
</tr>
<tr>
<td class="label">Location</td>
<td>[Basal forebrain](/brain-regions/basal-ganglia), [brainstem nuclei](/brain-regions/brainstem), spinal cord</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Cholinergic projection neurons</td>
</tr>
<tr>
<td class="label">Key Gene</td>
<td>[GYS1](/genes/gys1) (Muscle glycogen synthase)</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>Very rare (<1:1,000,000)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000108](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000108)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000108](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000108)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:4042028](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252F
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cholinergic Neurons in Adult Polyglucosan Body Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Glycogen Storage Disorders / Cholinergic System</td>
</tr>
<tr>
<td class="label">Location</td>
<td>[Basal forebrain](/brain-regions/basal-ganglia), [brainstem nuclei](/brain-regions/brainstem), spinal cord</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Cholinergic projection neurons</td>
</tr>
<tr>
<td class="label">Key Gene</td>
<td>[GYS1](/genes/gys1) (Muscle glycogen synthase)</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>Very rare (<1:1,000,000)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000108](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000108)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000108](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000108)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:4042028](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4042028)</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Brain Region</td>
</tr>
<tr>
<td class="label">Memory</td>
<td>Basal forebrain → Hippocampus</td>
</tr>
<tr>
<td class="label">Attention</td>
<td>Nucleus basalis → Cortex</td>
</tr>
<tr>
<td class="label">Motor control</td>
<td>Brainstem → Spinal cord</td>
</tr>
<tr>
<td class="label">Arousal</td>
<td>Pedunculopontine nucleus</td>
</tr>
<tr>
<td class="label">Normal Function</td>
<td>Disease State</td>
</tr>
<tr>
<td class="label">GYS1 expression: muscle, brain</td>
<td>Tissue-specific isoforms</td>
</tr>
<tr>
<td class="label">Normal glycogen synthesis</td>
<td>Polyglucosan accumulation</td>
</tr>
<tr>
<td class="label">Proper glycogen branching</td>
<td>Abnormal, poorly branched polysaccharide</td>
</tr>
<tr>
<td class="label">Energy storage</td>
<td>Toxic inclusion bodies</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Consequence</td>
</tr>
<tr>
<td class="label">Polyglucosan inclusions</td>
<td>Impaired axonal transport</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>Reduced energy supply</td>
</tr>
<tr>
<td class="label">Synaptic dysfunction</td>
<td>Acetylcholine release deficit</td>
</tr>
<tr>
<td class="label">Neurodegeneration</td>
<td>Cognitive impairment</td>
</tr>
<tr>
<td class="label">Nucleus</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Pedunculopontine</td>
<td>REM sleep, arousal</td>
</tr>
<tr>
<td class="label">Laterodorsal tegmental</td>
<td>Reward, attention</td>
</tr>
<tr>
<td class="label">Medial habenula</td>
<td>Mood, motivation</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Neurogenic bladder</td>
<td>Autonomic cholinergic dysfunction</td>
</tr>
<tr>
<td class="label">Peripheral neuropathy</td>
<td>Sensory neuron involvement</td>
</tr>
<tr>
<td class="label">Cerebellar ataxia</td>
<td>Purkinje cell, granule cell dysfunction</td>
</tr>
<tr>
<td class="label">Cognitive impairment</td>
<td>Basal forebrain cholinergic loss</td>
</tr>
<tr>
<td class="label">Muscle weakness</td>
<td>Motor neuron involvement</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Location</td>
</tr>
<tr>
<td class="label">T2 hyperintensity</td>
<td>White matter</td>
</tr>
<tr>
<td class="label">Atrophy</td>
<td>Brainstem, cerebellum</td>
</tr>
<tr>
<td class="label">Cervical cord thinning</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Supportive care</td>
<td>Symptoms</td>
</tr>
<tr>
<td class="label">Physical therapy</td>
<td>Mobility</td>
</tr>
<tr>
<td class="label">Bladder management</td>
<td>Neurogenic bladder</td>
</tr>
<tr>
<td class="label">Cognitive support</td>
<td>Memory</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Enzyme replacement</td>
<td>Theoretical</td>
</tr>
<tr>
<td class="label">Substrate reduction</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Autophagy enhancement</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Cholinergic neurons</td>
<td>Neuroprotective agents</td>
</tr>
<tr>
<td class="label">Acetylcholinesterase</td>
<td>Inhibitors (cautious use)</td>
</tr>
<tr>
<td class="label">Muscarinic receptors</td>
<td>Agonists (experimental)</td>
</tr>
<tr>
<td class="label">Nicotinic receptors</td>
<td>Modulators</td>
</tr>
</table>
[Adult Polyglucosan Body Disease (APBD)adult-polyglucosan-body-disease) is a rare glycogen storage disorder caused by mutations in the [GYS1 gene](/genes/gys1), leading to accumulation of abnormal glycogen (polyglucosan) in neurons and other cell types. [Cholinergic neurons](/cell-types/cholinergic-neurons), which are essential for cognitive function and motor control, are particularly vulnerable in this disorder. [@robain1997]
APBD shares features with AD:
<!-- multi-taxonomy-enrichment -->
Cholinergic neurons use acetylcholine (ACh) as their neurotransmitter and are critical for multiple brain functions:
APBD results from deficiency of muscle glycogen synthase (GYS1):
These neurons project to hippocampus and cortex:
Clinical correlation:
The study of Cholinergic Neurons In Adult Polyglucosan Body Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.